In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae

Rodríguez-Avial I, Pena I, Picazo JJ, Rodríguez-Avial C, Culebras E.

International Journal of Antimicrobial Agents , Volume 46 , Issue 6 , 616 - 621 DOI: http://dx.doi.org/10.1016/j.ijantimicag.2015.07.021

Access publication @ sciencedirect.com (purchase or paid subscription required)

Baseline Pathogens and Patient Outcomes in a Phase 2 Study Comparing Plazomicin (ACHN-490) to Levofloxacin in Complicated Urinary Tract Infection (cUTI) including Acute Pyelonephritis (AP)

Lynn E. Connolly, Alisa W. Serio, Valerie D. Riddle, Deborah S. Cebrik, Eliana S. Armstrong, Todd C. Clobes, and Kenneth J. Hillan
Achaogen, Inc. (South San Francisco, CA, USA), BioPharmAdvisors LLC, (Bumpass VA, USA), InClin, Inc. (San Mateo, CA, USA)
25th ECCMID, 2015; presentation # O200

Download presentation as PDF

 

In vitro bactericidal activity of aminoglycosides, including the next-generation drug plazomicin, against Brucella spp.

Olsen SC, Carlson SA

International Journal of Antimicrobial Agents , Volume 45 , Issue 1 , 76 - 78 DOI: http://dx.doi.org/10.1016/j.ijantimicag.2014.09.011

Access this publication @ sciencedirect.com (purchase or paid subscription required)